you didn't listen

[markado]

If one were to convert and back calculate scripts written (TRx) per week on Sanofi's watch into insulin units, vs scripts written on MNKD's watch per week into insulin units, how are we trending. Also, number of physicians writing scripts unique per week and total to date. Such metrics are needed to measure effectiveness of campaigns and sales efforts, and without such measures in place, management, shareholders and the market are in the dark.

[lojothehus]

1. Can you please explain the persistent silence from Mankind Management and their lack thereof to update shareholders with any type of information?

2. Will there or will there not ever be a television commercial?

3. Why hasn't Mankind sought interviews with major news and/or talk shows?

[reality]

Take your pick.

Q1. We know you have given away thousands of free samples including trials, from Sanofi, and with your attempt to commercialize the product. Also over the past three years or so you have sold thousands of new scripts. EXACTLY WHAT IS YOUR RETENTION/SCRIPT RENEWAL RATE? 1%, Less than 1%? And why?
Q2. You promised RLS milestones, who is RLS and when do we see significant milestones
Q3. You stated TWO companies that approached you after Sanofi left for partnerships. Why DID you not partner with them?
Q4. YOU have RUINED THE LIVES OF MANY SMALL TIME INVESTORS. DO YOU FEEL YOU, CCO or the BOD ARE QUALIFIED AND DESERVING OF A SINGLE CENT IN SALARY?
Q5. YOU RECEIVED $120M from Sanofi, WHY DO YOU FEEL IT IS NECESSARY TO ALLOW DEERFIELD TO GET A CASH BACK PAYMENT OF $4M when the average Joe won't get a cent?
Q6. Why do you feel you and your cohorts need a GOLDEN PARACHUTE?

[otherottawaguy]

Catch all for the posts to the ASM questions thread, title says it all.

[mytakeonit]

My two questions are ...

1. Why are there so many shorts here?
2. Why is it that shorts can't count to two?

[wgreystone]

Why is it so difficult for PWD to get Afrezza? Is it true that Afrezza is more expensive compared to RAA (considering PWD may use more Afrezza units to lower BG as they can (less afraid of going low))? What's the strategy that MNKD takes to change it (either improve label SOOON or lower Afrezza price??) ?

[sportsrancho]

Are the BOD and management ( Matt and Mike ) on the same page going forward as to how to market Afrezza?

Do they think targeting GP's would be a better plan, considering the stubborn Endo's?

[slugworth008]

Why hasn't a full time sales team been able to break 300 scripts per week - given the length of time they've been in the field.

How are you addressing the barriers to sales/scripts?

[anderson]

May 2, 2017 16:08:36 GMT -5 markado said:

If one were to convert and back calculate scripts written (TRx) per week on Sanofi's watch into insulin units, vs scripts written on MNKD's watch per week into insulin units, how are we trending. Also, number of physicians writing scripts unique per week and total to date. Such metrics are needed to measure effectiveness of campaigns and sales efforts, and without such measures in place, management, shareholders and the market are in the dark.

The only column you need to pay attention to is weekly sales $$$$$$.  The others you can play word games with but weekly sales is the one that counts.
Think we need to get Matt and Mike on the phone "Show Me the MONEY!"
www.youtube.com/watch?v=mBS0OWGUidc

[sayhey24]

1. Three years after approval afrezza seems to be working better than most people dreamed with basically no safety issues identified. Al Mann often talked about a small country which wanted $200M of afrezza. With such an amazing product which is often described as life changing is this small country still interested and when can we expect the deal to be closed?

2. In May 2015 several months into the Sanofi launch Stephen Schwarz was interviewed and asked for his option of the afrezza market and the lessons learned so far. Mr. Schwarz said afrezza meets a huge need in the T2 market as 70% are not hitting target goals but Sanofi needed a different approach for this market. Dr. Bruce Bode when asked about afrezza during a Medscape education session several weeks ago stated all T2s should be on afrezza within a year or 2 of diagnosis. Does Mannkind see the T2 market as viable and did Stephen Schwarz share his thoughts on the approach which would need to be taken?

3. Several years ago it was said Mannkind had an "Embarrassment of Riches". Since afrezza's affect on PWD's lives is exceeding expectations can you share Two of these embarrassments with us aside from the stock price?

[slugworth008]

May 2, 2017 19:07:55 GMT -5 anderson said:

May 2, 2017 18:55:24 GMT -5 slugworth008 said:

Why hasn't a full time sales team been able to break 300 scripts per week - given the length of time they've been in the field.

How are you addressing the barriers to sales/scripts?

Same as above just asked differently.
Revenue and scripts have been the same for over a year.  The sales team wither contract or full time have not be able to increase these numbers.  The steady state has to be due to drop outs, so why are there so many people who drop out of using Afrezza and what can be done to address this? 

  My bad - didn't see that - thanks!

[saxcmann]

1. Why won't you sell mnkd since sales efforts have clearly failed?

2. Have there been offers in the past to buyout mnkd? If so, who and how much?

[blueice]

1. How close are we to "Epic"?

[lakers]

IR replied,

We are in a quiet period until our earnings call on May 10....please listen to the call. Some of your questions may be answered

[bioexec25]

There have been 20 potential catalysts/pipeline (read list) for growth mentioned over the past 3 years. Can you explain why not one of them have materialized?

Why does the drop-out rate continue to be extremely high, well beyond any dosing, access or cost spin?